Research programme: calcium channel modulators - GrunenthalAlternative Names: Cav2.2 modulators - Grunenthal; Pain – Cav2.2 - Grunenthal
Latest Information Update: 16 Jul 2016
At a glance
- Originator Grunenthal
- Class Analgesics
- Mechanism of Action Calcium channel modulators
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- No development reported Pain
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for research development in Pain in Germany
- 19 Apr 2013 Early research in Pain in Germany (unspecified route)